Bavarian Nordic A/S announced that the European Health Emergency Preparedness and Response Authority (HERA) has ordered an additional 170,000 doses of MVA-BN smallpox/monkeypox vaccine, which will be made available to EU Member States, Norway and Iceland. With deliveries scheduled before year-end, the new order will double the supply of monkeypox vaccines to HERA in 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
148.1 DKK | +2.74% | +0.48% | -16.57% |
Mar. 13 | Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults | MT |
Mar. 13 | Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.57% | 1.61B | |
+24.35% | 653B | |
+25.58% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+12.84% | 233B | |
+5.11% | 201B | |
-9.94% | 193B | |
-6.47% | 144B |
- Stock Market
- Equities
- BAVA Stock
- News Bavarian Nordic A/S
- Bavarian Nordic A/S Enters Additional Monkeypox Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority